C4 Therapeutics, Inc. (CCCC) Current Ratio
- Current ratio · latest quarter: Value 5.45×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.45× | Current assets / current liabilities. $262.90M ÷ $48.25M ≈ 5.45× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 262.90M USD | Assets, Current |
| Current obligations | 48.25M USD | Liabilities, Current |
| Cash and equivalents | 78.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 1.33M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.12M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $262.90M | $48.25M | $78.61M | (m) | $1.33M | (m) | $1.12M | (m) | 5.45× |
| 2026-03-31 | $245.37M | $27.25M | $61.27M | (m) | $2.88M | (m) | $773.00K | (m) | 9.00× |
| 2025-12-31 | $258.11M | $33.03M | $74.60M | (m) | $2.40M | (m) | $858.00K | (m) | 7.81× |
| 2025-09-30 | $206.86M | $35.95M | $58.81M | (m) | $6.54M | (m) | $1.33M | (m) | 5.76× |
| 2025-06-30 | $224.73M | $44.46M | $78.16M | (m) | $2.16M | (m) | $2.22M | (m) | 5.06× |
| 2025-03-31 | $232.53M | $40.82M | $51.29M | (m) | $8.03M | (m) | $683.00K | (m) | 5.70× |
| 2024-12-31 | $257.77M | $45.18M | $55.50M | (m) | $3.10M | (m) | $1.33M | (m) | 5.71× |
| 2024-09-30 | $273.23M | $43.29M | $59.65M | (m) | $10.34M | (m) | $1.50M | (m) | 6.31× |
| 2024-06-30 | $276.04M | $54.20M | $73.11M | (m) | $1.17M | (m) | $913.00K | (m) | 5.09× |
| 2024-03-31 | $279.59M | $55.02M | $89.66M | (m) | $13.60M | (m) | $1.63M | (m) | 5.08× |
| 2023-12-31 | $271.19M | $42.77M | $126.59M | (m) | $11.80M | (m) | $1.45M | (m) | 6.34× |
| 2023-09-30 | $223.69M | $30.27M | $60.97M | (m) | $500.00K | (m) | $1.28M | $0.00 | 7.39× |
| 2023-06-30 | $274.39M | $48.24M | $44.88M | (m) | $1.03M | (m) | $2.25M | $10.34M | 5.69× |
| 2023-03-31 | $278.45M | $39.38M | $49.48M | (m) | $528.00K | (m) | $1.03M | $2.29M | 7.07× |
| 2022-12-31 | $287.56M | $44.55M | $29.75M | (m) | $1.47M | (m) | $1.17M | $2.29M | 6.46× |
| 2022-09-30 | $325.46M | $45.27M | $49.55M | $264.10M | $1.49M | (m) | $2.37M | $2.25M | 7.19× |
| 2022-06-30 | $318.37M | $46.15M | $57.30M | $250.48M | $1.71M | (m) | $4.45M | $750.00K | 6.90× |
| 2022-03-31 | $302.95M | $46.99M | $46.00M | $245.17M | $1.77M | (m) | $3.40M | $750.00K | 6.45× |
| 2021-12-31 | $325.69M | $51.25M | $76.12M | (m) | $5.72M | (m) | $4.51M | $0.00 | 6.36× |
| 2021-09-30 | $412.29M | $48.69M | $162.75M | $239.33M | $4.84M | (m) | $3.75M | (m) | 8.47× |
| 2021-06-30 | $477.56M | $44.17M | $281.15M | $184.76M | $6.21M | (m) | $4.47M | (m) | 10.81× |
| 2021-03-31 | $322.01M | $37.65M | $94.91M | $218.57M | $3.66M | (m) | $3.74M | (m) | 8.55× |
| 2020-12-31 | $381.01M | $43.85M | $181.73M | $189.96M | $4.48M | (m) | $5.68M | (m) | 8.69× |
| 2020-09-30 | $208.92M | $40.01M | $63.43M | (m) | $4.14M | (m) | $5.26M | (m) | 5.22× |
| 2019-12-31 | $96.77M | $33.64M | $90.55M | (m) | $4.62M | (m) | $5.38M | (m) | 2.88× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |